Severe serum sickness-like syndrome after omalizumab therapy for asthma

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Pilette, Charles [UCL] Coppens, Nathalie [UCL] Houssiau, Frédéric [UCL] Rodenstein, Daniel [UCL]

Document type	Article de périodique (Journal article) – Lettre à l'éditeur
Access type	Accès restreint
Publication date	2007
Language	Anglais
Journal information	"Journal of Allergy and Clinical Immunology" - Vol. 120, no. 4, p. 972-973 (2007)
Peer reviewed	yes
Publisher	Mosby, Inc. (Philadelphia)
issn	0091-6749
e-issn	1097-6825
Publication status	Publié
Affiliations	UCL - MD/MINT - Département de médecine interne UCL - (SLuc) Service de pneumologie UCL - (SLuc) Service de rhumatologie UCL - (SLuc) Centre de l'allergie
MESH Subject	Syndrome ; Serum Sickness - chemically induced ; Humans ; Female ; Asthma - drug therapy ; Antibodies, Monoclonal - adverse effects ; Anti-Asthmatic Agents - adverse effects ; Aged
Links	http://www.ncbi.nlm.nih.gov/pubmed/17716723[PubMed] https://doi.org/10.1016/j.jaci.2007.06.038[DOI] http://hdl.handle.net/2078.1/37286[Handle]

Bibliographic reference	Pilette, Charles ; Coppens, Nathalie ; Houssiau, Frédéric ; Rodenstein, Daniel. Severe serum sickness-like syndrome after omalizumab therapy for asthma. In: Journal of Allergy and Clinical Immunology, Vol. 120, no. 4, p. 972-973 (2007)
Permanent URL	http://hdl.handle.net/2078.1/37286